New drugs to prevent acute kidney injury
About the Company
Arch is the leader in the development of peptides, antibodies and small molecules that target acute kidney injury (AKI) and organ inflammation injury caused by the enzyme Dipeptidase-1 (DPEP1).
Holding a suite of patented DPEP1 inhibiting drug candidates designed to prevent organ injury caused by inflammation, the company is developing a drug platform to inhibit injury in the kidneys, lungs and liver.
The company is aggressively pursuing the development of Acute Kidney Injury (AKI) treatments as its primary endpoint for commercializing its two lead drug candidates. Together, LSALT peptide and Cilastatin have the potential to significantly improve outcomes for up to 60% of all patients susceptible to AKI.
More broadly, organ inflammation is a common driver of injury and disease, with no effective treatments available in the market today. AKI represents an ideal initial focus for Arch’s lead drug candidates, as success in this area could pave the way for broader use in treating inflammation across other indications such as lung or liver inflammation injury, other AKI indications and septic shock.
- There are no effective drug treatments for acute organ inflammation on the market.
- The global anti-inflammatory therapeutics market size was approximately $102.37 billion (USD) in 2022, it’s expected to reach USD $127.5 billion by 2030.
Our platform
In August 2019, a scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins published a paper in the journal Cell (2019). The team identified DPEP1 for the first time as a major leukocyte (white blood cell) adhesion receptor on the lung, liver and kidney endothelium.
In the publication, DPEP1 was also identified as the target of LSALT peptide (the company’s lead drug candidate), differing from typical anti-inflammatory drugs by targeting this novel adhesion receptor rather than targeting individual cytokines.
- The company holds a strong patent position for its two lead drug candidates LSALT peptide and Cilastatin, two DPEP1 inhibitors with the potential to play a major role preventing acute kidney injury (AKI).
- Six million people are affected annually by AKI in the U.S. There is no treatment for kidney failure – patients require dialysis or a kidney transplant to survive.
- Approval of LSALT peptide to treat cardiac surgery-associated acute kidney injury (CS-AKI) will enable off-label use for other indications such as lung or liver inflammation injury, other AKI indications and septic shock.
- Cilastatin was originally developed by Merck to protect one of their antibiotics from being degraded by DPEP1. The drug has been shown to play a major role in toxin related kidney injury.
Arch Biopartners approach
Arch has a long history of working closely with the scientific community, universities and research institutions. The company’s mission is to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors.
An experienced group of scientists with an executive, board and advisors bringing deep scientific, pharmaceutical, biotechnology and corporate financial experience.
Science and Research TEAMS
- Current work on LSALT peptide and Cilastatin is directed by Arch’s larger Treatments for Inflammation Team, led by Dr. Daniel Muruve (Arch Biopartners CSO), Dr. Justin Macdonald Ph. D., and Dr. Arthur Lau Ph. D (Arch Biopartners Project Director), who are primarily based at the University of Calgary. David Luke, BScPhm, PharmD, is a Strategic Advisor and Senior Clinical Lead working to support the Board of Directors and the company’s ongoing clinical trials with LSALT peptide.
- The DPEP1 Inflammation Pathway and LSALT Peptide were discovered by the LSALT and DPEP1 team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D., Jennifer Rahn B Sc., M Sc. and their colleague Dr. Paul Kubes at the University of Calgary.
Executive, Board of Directors and Advisors
- Executives and Founders, CEO Richard Muruve, CSO Dr. Daniel Muruve and CFO Andrew Bishop form the management team
- Board of Directors, includes a group of key directors and strategic advisors
Find key information in the Arch Biopartners Investor Hub. While you’re there, please subscribe to receive the latest Investor News and Science alerts from the company.
- Stock Performance – Information about ARCH.V and ACHFF with historical and current price data (15 min delay)
- Press Releases – All the company’s news releases, material disclosures and alerts are provided in a complete archive for browsing and research
- Reports and Filings – Management’s Discussion and Analysis, Management’s Information Circulars, Financials and other SEDAR filings are available for download
- Investor Information – Auditor, Transfer Agent, Investor Relations Contact information
